AU2019394956B2 - Methods of treating neurological and psychiatric disorders - Google Patents

Methods of treating neurological and psychiatric disorders Download PDF

Info

Publication number
AU2019394956B2
AU2019394956B2 AU2019394956A AU2019394956A AU2019394956B2 AU 2019394956 B2 AU2019394956 B2 AU 2019394956B2 AU 2019394956 A AU2019394956 A AU 2019394956A AU 2019394956 A AU2019394956 A AU 2019394956A AU 2019394956 B2 AU2019394956 B2 AU 2019394956B2
Authority
AU
Australia
Prior art keywords
compound
disorder
patient
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019394956A
Other languages
English (en)
Other versions
AU2019394956A1 (en
Inventor
Seth Cabot Hopkins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma America Inc
Original Assignee
Sumitomo Pharma America Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharma America Inc filed Critical Sumitomo Pharma America Inc
Publication of AU2019394956A1 publication Critical patent/AU2019394956A1/en
Application granted granted Critical
Publication of AU2019394956B2 publication Critical patent/AU2019394956B2/en
Priority to AU2025213591A priority Critical patent/AU2025213591A1/en
Assigned to SUMITOMO PHARMA AMERICA, INC. reassignment SUMITOMO PHARMA AMERICA, INC. Request for Assignment Assignors: SUNOVION PHARMACEUTICALS INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2019394956A 2018-12-06 2019-12-05 Methods of treating neurological and psychiatric disorders Active AU2019394956B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025213591A AU2025213591A1 (en) 2018-12-06 2025-08-06 Methods of treating neurological and psychiatric disorders

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862776247P 2018-12-06 2018-12-06
US62/776,247 2018-12-06
US201962829796P 2019-04-05 2019-04-05
US62/829,796 2019-04-05
PCT/US2019/064646 WO2020118032A1 (en) 2018-12-06 2019-12-05 Methods of treating neurological and psychiatric disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025213591A Division AU2025213591A1 (en) 2018-12-06 2025-08-06 Methods of treating neurological and psychiatric disorders

Publications (2)

Publication Number Publication Date
AU2019394956A1 AU2019394956A1 (en) 2021-06-17
AU2019394956B2 true AU2019394956B2 (en) 2025-05-08

Family

ID=69024675

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019394956A Active AU2019394956B2 (en) 2018-12-06 2019-12-05 Methods of treating neurological and psychiatric disorders
AU2025213591A Pending AU2025213591A1 (en) 2018-12-06 2025-08-06 Methods of treating neurological and psychiatric disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025213591A Pending AU2025213591A1 (en) 2018-12-06 2025-08-06 Methods of treating neurological and psychiatric disorders

Country Status (9)

Country Link
US (3) US20200179336A1 (https=)
EP (1) EP3890726A1 (https=)
JP (2) JP2022511509A (https=)
KR (1) KR20210100667A (https=)
CN (2) CN118576586A (https=)
AU (2) AU2019394956B2 (https=)
CA (1) CA3122261A1 (https=)
MX (1) MX2021006553A (https=)
WO (1) WO2020118032A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201510665WA (en) 2009-12-04 2016-01-28 Sunovion Pharmaceuticals Inc Multicycle Compounds And Pharmaceutical Compositions Useful For The Treatment Of Neurological Disorders
MA45795A (fr) 2016-07-29 2019-06-05 Sunovion Pharmaceuticals Inc Composés et compositions, et utilisations associées
MX390141B (es) 2017-02-16 2025-03-20 Sunovion Pharmaceuticals Inc Metodos para tratar esquizofrenia
CA3070993C (en) 2017-08-02 2025-05-20 Sunovion Pharmaceuticals Inc. ISOCHROMANE COMPOUNDS AND THEIR USES
UA130249C2 (uk) 2018-02-16 2025-12-31 Сумітомо Фарма Америка, Інк. Солі, кристалічні форми і способи їх отримання
CA3180115A1 (en) 2020-04-14 2021-10-21 Sunovion Pharmaceuticals Inc. (s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine for treating neurological and psychiatric disorders
US20220165391A1 (en) * 2020-11-25 2022-05-26 Kyndryl, Inc. Multi-stage treatment recommendations
AU2022348905A1 (en) 2021-09-23 2024-04-11 Sumitomo Pharma America, Inc. Methods of treating metabolic disorders
CA3260160A1 (en) 2022-08-30 2024-03-07 Sumitomo Pharma America, Inc. ULOTARONT FOR THE ADJUVANT TREATMENT OF MAJOR DEPRESSIVE DISORDER
AU2023358704A1 (en) 2022-10-13 2025-05-29 Sumitomo Pharma America, Inc. Methods of reducing physical dependence to neuropsychiatric treatments
KR20250088777A (ko) 2022-10-28 2025-06-17 스미토모 파마 아메리카, 인크. 불안 및 연관된 상태를 치료하기 위한 울로타론트
WO2024107681A1 (en) 2022-11-15 2024-05-23 Sumitomo Pharma America, Inc. Methods of switching neuropsychiatric medications using ulotaront
CN115754079B (zh) * 2022-11-28 2025-04-04 合肥和合医疗科技有限公司 一种同时检测7种精神药物及其代谢产物含量的方法
CN117594119B (zh) * 2024-01-17 2024-05-10 北京大学第六医院 用于预测帕罗西汀或其药用盐对抑郁或焦虑症患者疗效的装置
WO2025252814A1 (en) 2024-06-04 2025-12-11 Duc Duy Vo Methods for treating trace amine-associated receptor 1 (taar1)-associated diseases or disorders comprising administration of novel taar1 agonists or pharmaceutical compositions thereof
WO2026015878A1 (en) * 2024-07-12 2026-01-15 Mindx Therapeutics, Inc. A new combination therapy for treatment-resistant depression in patients with co-morbid metabolic syndrome

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011069063A2 (en) * 2009-12-04 2011-06-09 Sunovion Pharmaceuticals, Inc. Multicyclic compounds and methods of use thereof
WO2018151861A1 (en) * 2017-02-16 2018-08-23 Sunovion Pharamaceuticials Inc. Methods of treating schizophrenia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA130249C2 (uk) 2018-02-16 2025-12-31 Сумітомо Фарма Америка, Інк. Солі, кристалічні форми і способи їх отримання
JP2021513972A (ja) * 2018-02-16 2021-06-03 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 社会的機能障害の治療方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011069063A2 (en) * 2009-12-04 2011-06-09 Sunovion Pharmaceuticals, Inc. Multicyclic compounds and methods of use thereof
WO2018151861A1 (en) * 2017-02-16 2018-08-23 Sunovion Pharamaceuticials Inc. Methods of treating schizophrenia

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KOBLAN KENNETH ET AL: "A Phase 1 Open Label Safety and Tolerability Study of SEP-363856, a Novel NON-D2 Mechanism of Action Molecule, in Patients With Schizophrenia", NEUROPSYCHOPHARMACOLOGY, vol. 41, no. Suppl. 1, December 2016 *

Also Published As

Publication number Publication date
AU2025213591A1 (en) 2025-08-21
JP2022511509A (ja) 2022-01-31
AU2019394956A1 (en) 2021-06-17
KR20210100667A (ko) 2021-08-17
CA3122261A1 (en) 2020-06-11
US20240350453A1 (en) 2024-10-24
US20250312308A1 (en) 2025-10-09
WO2020118032A1 (en) 2020-06-11
MX2021006553A (es) 2021-09-08
US20200179336A1 (en) 2020-06-11
JP2025024102A (ja) 2025-02-19
EP3890726A1 (en) 2021-10-13
CN118576586A (zh) 2024-09-03
CN113271936A (zh) 2021-08-17

Similar Documents

Publication Publication Date Title
AU2019394956B2 (en) Methods of treating neurological and psychiatric disorders
EP4135690B1 (en) (s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine for treating, preventing and/or managing a neurological and/or psychiatric disorder
AU2018201060B2 (en) 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto
RU2757221C2 (ru) Фармацевтические композиции, содержащие антипсихотическое лекарственное средство и ингибитор vmat2, и их применение
CN114340670B (zh) T-型钙通道调节剂的制剂及其使用方法
US12161758B2 (en) Modified release formulations and uses thereof
UA122780C2 (uk) Композиції, що містять 2-((1-(2-(4-фторфеніл)-2-оксоетил)піперидин-4-іл)метил)ізоіндолін-1-он, для лікування шизофренії
CN115776894A (zh) T型钙通道调节剂的使用方法
MX2008000250A (es) Combinaciones de eszopiclona y trans-4-(3,4-diclorofenil)-1,2,3,4- tetrahidro-n-metil-1-naftalenamina o trans 4-(3,4-diclorofenil)-1, 2,3,4-tetrahidro-1-naftalenamina y metodos de tratamiento de menopausia y trastornos del estado de animo, ansiedad y
HK40057761A (en) Methods of treating neurological and psychiatric disorders
JP2023503271A (ja) （２ｒ，６ｒ）－ヒドロキシノルケタミンの塩、それらの結晶形、およびその製造方法
JP2022087834A (ja) 放出調節製剤およびその使用
HK40064212A (en) Modified release formulations and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: SUMITOMO PHARMA AMERICA, INC.

Free format text: FORMER OWNER(S): SUNOVION PHARMACEUTICALS INC.